Association of British Clinical Diabetologists (ABCD) position statement on the risk of diabetic ketoacidosis associated with the use of sodium-glucose cotransporter-2 inhibitors
BRITISH JOURNAL OF DIABETES(2016)
摘要
Diabetic Ketoacidosis (DKA) has been reported in patients with diabetes taking SGLT-2 inhibitor drugs both in clinical trials and in real life situations, particularly amongst patients taking insulin. The US Food and Drug Administration (FDA) has issued a safety communication following 20 cases of DKA in patients receiving these drugs. 1 This concern has also prompted an American Association of Clinical Endocrinologists and American College of Endocrinology position statement covering the use of SGLT-2 inhibitors in people with type 2 diabetes. 2 The following is the ABCD position statement on this issue.
更多查看译文
关键词
SGLT-2 inhibitors,diabetic ketoacidosis,ABCD
AI 理解论文
溯源树
样例
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要